Methotrexate is a strong medicine. The FDA approved it to treat adults with severe, disabling psoriasis that cannot be controlled with medicine applied to the skin or light treatments. Methotrexate ...

Please provide your email address to receive an email when new articles are posted on . Patients with psoriasis taking methotrexate were 2.8 times more likely to develop nonmelanoma skin cancer than ...

Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...

An article published in the International Journal of Dermatology evaluated the drug survival of methotrexate in patients with psoriasis. This single-center retrospective study assessed the clinical ...

A consensus reached by nearly 200 international experts in dermatology supports specific methotrexate dosing recommendations for the treatment of psoriasis in most adults with the disorder and certain ...

Psoriasis is a condition in which skin cells are produced much faster than normal. The body cannot shed the cells fast enough, resulting in patches (plaques) of scaly, thick skin. Investigators ...

Patients with psoriasis taking methotrexate are nearly 3 times as likely to develop non-melanoma skin cancer than patients not taking the treatment. Patients with psoriasis who are treated with ...

When you have psoriasis, your immune system sends out signals that cause your skin cells to renew themselves too fast. This too-active immune response is what makes scales and red patches form on your ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

In adults with psoriasis, adding methotrexate to adalimumab did not improve effectiveness or drug survival compared with adalimumab alone, according to a UK cohort study of patients with plaque ...